MDCX

Handel nachbörslich: 1.86 0.06 +3.33%

Medicus Pharma Ltd (MDCX)

Überblick Nachrichten Preisverlauf Forum Prognose

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Medicus Pharma Ltd Stock (MDCX) Company Profile

Medicus Pharma Ltd

Healthcare (1129)

610-540-7515

300 CONSHOHOCKEN STATE RD., W. CONSHOHOCKEN

Nächster Verdiensttermin

Neueste SEC-Einreichungen

MDCX's Discussions on Twitter

Vergleichen Sie MDCX mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
MDCX Medicus Pharma Ltd	1.80	45.22M	0	-16.51M	-15.68M	-1.3528
LLY Lilly Eli Co	1,054.29	950.68B	59.42B	18.41B	6.44B	20.22
JNJ Johnson Johnson	209.30	516.00B	92.15B	25.12B	20.46B	10.36
ABBV Abbvie Inc	223.67	401.99B	59.64B	2.36B	19.68B	1.3253
NVS Novartis Ag Adr	135.03	259.40B	54.45B	14.42B	17.15B	7.333
MRK Merck Co Inc	98.27	248.85B	63.90B	19.05B	13.05B	7.5596

Medicus Pharma Ltd Aktie (MDCX) Neueste Nachrichten

Finanzdaten der Medicus Pharma Ltd-Aktie (MDCX)

Medicus Pharma Ltd (MDCX)

Medicus Pharma Ltd Stock (MDCX) Company Profile

Vergleichen Sie MDCX mit anderen Aktien

Medicus Pharma Ltd Aktie (MDCX) Neueste Nachrichten

Medicus Pharma completes patient enrollment for phase 2 BCC treatment study - MSN

Medicus Pharma completes enrollment in Phase 2 skin cancer microneedle study - Proactive financial news

Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement - Columbia Daily Tribune

Medicus Pharma Ltd Announces a Definitive Agreement to Acquire Antev Ltd. UK - TMX Newsfile

Medicus Pharma Completes Phase 2 Enrollment of D-MNA Study to Non-Invasively Treat BCC - Dermatology Times

Small cap wrap: EnWave, Medicus Pharma, Ocean Power Technologies, EDM Resources, C3 Metals… - Proactive financial news

Medicus Pharma completes enrollment for Phase 2 basal cell carcinoma study - Proactive financial news

Medicus Pharma Completes Patient Enrollment for Phase 2 BCC Treatment Study - TipRanks

Medicus Pharma (MDCX) Analyst Rating Maintained by D. Boral Capi - GuruFocus

Medicus Pharma completes enrollment of 90 patients for Phase 2 study - TipRanks

Medicus Pharma Ltd. Completes Enrolment of Ninety (90) Patients for Phase 2 Clinical Study (SKNJCT-003) to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin - The Manila Times

Medicus Pharma Ltd. Completes Enrolment of Ninety (90) - GlobeNewswire

Medicus Pharma Ltd. Receives Full United Kingdom Regulatory and Ethical Approvals To Expand Phase 2 Clinical Study (SKNJCT-003) To Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin - Greenville Online

Medicus Pharma Ltd. to Present at The Maxim Growth Summit 2025 - Victorville Daily Press

Medicus Pharma’s Warrant Inducement Agreement Announced - TipRanks

Medicus Pharma Elevates President Carolyn Bonner to CFO as Clinical Pipeline Accelerates - MyChesCo

Medicus Pharma Ltd. To Present at Brookline Capital Markets - Daytona Beach News-Journal

Medicus Pharma Ltd. to Present at the Family Office Summit in Dubai, UAE - Daytona Beach News-Journal

Medicus Pharma Ltd. Announces First Patient Treated in United Arab Emirates (UAE) Sknjct-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin - The Asheville Citizen Times

Medicus Pharma Ltd. Announces $8.0 Million Non-Dilutive Debenture Financing - The Times Telegram

Medicus Pharma Ltd. Receives Positive Feedback From the Food and Drug Adminstration (FDA) Type C Meeting Supporting the Development of Skinject - Daytona Beach News-Journal

Medicus Pharma secures $5.1 million from warrant exercise agreement By Investing.com - Investing.com Nigeria

Medicus Pharma secures $5.1 million from warrant exercise agreement - Investing.com India

Finanzdaten der Medicus Pharma Ltd-Aktie (MDCX)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie MDCX